PharmaCyte Biotech, Inc. Contracts & Agreements
91 Contracts & Agreements
- Business Finance (37 contracts)
- Business Operations (9)
- Human Resources (12)
- Intellectual Property (3)
- Uncategorized (30)
- Form of Series A Warrant (Filed With SEC on November 16, 2023)
- Form of Series B Warrant (Filed With SEC on November 16, 2023)
- Form of Purchase Agreement (Filed With SEC on November 16, 2023)
- Form of Convertible Note (Filed With SEC on November 16, 2023)
- Form of Registration Rights Agreement (Filed With SEC on November 16, 2023)
- Form of Collaboration Agreement (Filed With SEC on November 16, 2023)
- Form of Warrant (Filed With SEC on May 11, 2023)
- Form of Purchase Agreement (Filed With SEC on May 11, 2023)
- Form of Registration Rights Agreement (Filed With SEC on May 11, 2023)
- Engagement Letter, dated May 9, 2023 by and between Synaptogenix, Inc. and Katalyst Securities LLC (Filed With SEC on May 11, 2023)
- Release Agreement, dated October 12, 2022, by and between PharmaCyte Biotech, Inc. and Gerald W. Crabtree (Filed With SEC on October 14, 2022)
- Separation, Consulting and Release Agreement, dated October 6, 2022, by and between PharmaCyte Biotech, Inc. and Kenneth L. Waggoner (Filed With SEC on October 7, 2022)
- Cooperation Agreement dated August 15, 2022, by and between PharmaCyte Biotech, Inc. and Iroquois Master Fund Ltd. and its affiliates (Filed With SEC on August 16, 2022)
- Form of Director Offer Letter (Filed With SEC on August 16, 2022)
- Description of Securities (Filed With SEC on July 28, 2022)
- Amended and Restated Executive Compensation Agreement, dated May 8, 2022, between Kenneth L. Waggoner and the Company (Filed With SEC on July 28, 2022)
- Amended and Restated Executive Compensation Agreement, dated May 8, 2022, between Carlos A. Trujillo and the Company (Filed With SEC on July 28, 2022)
- PharmaCyte Biotech, Inc. 2021 Equity Incentive Plan (Filed With SEC on July 28, 2022)
- Form of Pre-Funded Common Stock Purchase Warrant (Filed With SEC on August 23, 2021)
- Form of Series A Warrant Common Stock Purchase Warrant (Filed With SEC on August 23, 2021)
- Form of Placement Agent Common Stock Purchase Warrant (Filed With SEC on August 23, 2021)
- Securities Purchase Agreement, dated as of August 19, 2021 (Filed With SEC on August 23, 2021)
- Underwriting Agreement, dated as of August 9, 2021 (Filed With SEC on August 12, 2021)
- Form of Common Warrant (Filed With SEC on August 12, 2021)
- Form of Pre-funded Warrant (Filed With SEC on August 12, 2021)
- Form of Underwriters Warrant (Filed With SEC on August 12, 2021)
- Description of Securities (Filed With SEC on August 10, 2021)
- Amendment No. 3, dated as of October 14, 2020, to Executive Compensation Agreement between Gerald W. Crabtree and the Company (Filed With SEC on October 16, 2020)
- Right of First Refusal Agreement by and between PharmaCyte Biotech, Inc. and Silver Rock Associates, Inc., dated May 4, 2020 (Filed With SEC on September 11, 2020)
- Amendment No. 1 to Right of First Refusal Agreement by and between PharmaCyte Biotech, Inc. and Silver Rock Associates, Inc., dated July 15, 2020 (Filed With SEC on September 11, 2020)
- Share Subscription Agreement between the Company and the Investor dated January 17, 2020 (Filed With SEC on January 21, 2020)
- Fourth Amendment to Asset Purchase Agreement between the Company, S.G. Austria Pte. Ltd. and Austrianova Singapore Pte. Ltd. effective May 14, 2018 (Filed With SEC on May 15, 2018)
- Third Amendment to Licensing Agreement between the Company and Austrianova Singapore Pte. Ltd. effective May 14, 2018 (Filed With SEC on May 15, 2018)
- Second Amendment to Licensing Agreement between the Company and Austrianova Singapore Pte. Ltd. effective May 14, 2018 (Filed With SEC on May 15, 2018)
- Financial Advisory, Offering and At-the-Market Offering Engagement Letter dated February 22, 2018, by and between PharmaCyte Biotech, Inc. and Aeon Capital, Inc (Filed With SEC on February 22, 2018)
- Mutual Termination Agreement dated January 26, 2018, by and between PharmaCyte Biotech, Inc. and Chardan Capital Markets, LLC (Filed With SEC on February 22, 2018)
- Letter Agreement between the Company and Dr. Tong dated October 9, 2017 (Filed With SEC on October 10, 2017)
- Binding Term Sheet between Austrianova Singapore Pte. Ltd. andSG Austria Pte. Ltd. and PharmaCyte Biotech, Inc. (Filed With SEC on September 6, 2017)
- [Signaturepage follows] (Filed With SEC on July 10, 2017)
- [Signature page to follow] (Filed With SEC on May 2, 2017)
- AMENDMENT NO. 2 TO EXECUTIVE COMPENSATIONAGREEMENT (Filed With SEC on March 13, 2017)
- AMENDMENTNo. 2 TO executive Compensation AGREEMENT (Filed With SEC on March 13, 2017)
- AMENDMENT NO. 2 TO EXECUTIVECOMPENSATION AGREEMENT (Filed With SEC on March 13, 2017)
- FOURTHSTOCK OPTION AGREEMENT (Filed With SEC on March 13, 2017)
- ThirdSTOCK OPTION AGREEMENT (Filed With SEC on March 13, 2017)
- FOURTHSTOCK OPTION AGREEMENT (Filed With SEC on March 13, 2017)
- 23046 Avenida de la Carlota| Suite 600 | Laguna Hills | California 92653 Office: 917 ###-###-#### |Fax: 917 ###-###-#### | Mobile: 917 ###-###-#### | ***@*** (Filed With SEC on March 13, 2017)
- CHARDAN CAPITAL MARKETS (Filed With SEC on December 21, 2016)
- SECOND AMENDMENT TO LICENSE AGREEMENT Relating to Encapsulated Cells Producing Viral Particles and Encapsulated Cells Expressing Biomolecules LICENSORS Bavarian Nordic A/S, reg.... (Filed With SEC on December 2, 2016)
- First Amendment toLicensing Agreement (Filed With SEC on July 29, 2016)
- SecondAmendment toLicensingAgreement (Filed With SEC on July 29, 2016)
- First Amendmentto Licensing Agreement (Filed With SEC on July 29, 2016)
- BINDING MEMORANDUM OF UNDERSTANDING (Filed With SEC on July 29, 2016)
- AMENDMENT NO. 1 TO EXECUTIVE COMPENSATIONAGREEMENT (Filed With SEC on March 8, 2016)
- AMENDMENT NO. 1 TO EXECUTIVE COMPENSATIONAGREEMENT (Filed With SEC on March 8, 2016)
- THIRD STOCK OPTION AGREEMENT (Filed With SEC on March 8, 2016)
- THIRD STOCK OPTION AGREEMENT (Filed With SEC on March 8, 2016)
- PHARMACYTE BIOTECH, INC. COMMON STOCK WARRANT AGREEMENT (Filed With SEC on January 12, 2016)
- PHARMACYTE BIOTECH, INC. COMMON STOCK WARRANT AGREEMENT (Filed With SEC on January 12, 2016)
- STOCK AND WARRANT PURCHASE AGREEMENT (Filed With SEC on January 12, 2016)
- STOCK AND WARRANT PURCHASE AGREEMENT (Filed With SEC on January 12, 2016)
- 12510 Prosperity Drive | Suite 310 | SilverSpring | Maryland 20904-1643 Office: 917 ###-###-#### | Fax: 917 ###-###-####| Mobile: 917 ###-###-#### | ***@*** (Filed With SEC on April 29, 2015)
- ExecutiveCompensation AGREEMENT (Filed With SEC on March 13, 2015)
- FIRST stock option agreement (Filed With SEC on March 13, 2015)
- SECOND stock option agreement (Filed With SEC on March 13, 2015)
- ExecutiveCompensation AGREEMENT (Filed With SEC on March 13, 2015)
- FIRST stock option agreement (Filed With SEC on March 13, 2015)
- Second stock option agreement (Filed With SEC on March 13, 2015)
- Licensing Agreement (Filed With SEC on December 15, 2014)
- Consulting Agreement (Filed With SEC on October 3, 2014)
- stock option agreement (Filed With SEC on October 3, 2014)
- Consulting Agreement (Filed With SEC on October 3, 2014)
- stock option agreement (Filed With SEC on October 3, 2014)
- Consulting Agreement (Filed With SEC on October 3, 2014)
- stock option agreement (Filed With SEC on October 3, 2014)
- SETTLEMENT AGREEMENT (Filed With SEC on September 25, 2014)
- ASSET PURCHASE AGREEMENT (Filed With SEC on September 25, 2014)
- LICENSE AGREEMENT Relating to Encapsulated Cells Producing Viral Particles and Encapsulated Cells Expressing Biomolecules LICENSORS BAVARIAN NORDIC A/S, reg. no.16271187, a... (Filed With SEC on August 4, 2014)
- AMENDMENT TO LICENSE AGREEMENT Relating to Encapsulated Cells Producing Viral Particles and Encapsulated Cells Expressing Biomolecules LICENSORS BAVARIAN NORDIC A/S, reg.... (Filed With SEC on August 4, 2014)
- MANUFACTURING FRAMEWORK AGREEMENT (Filed With SEC on August 4, 2014)
- MASTER SERVICES AGREEMENT (Filed With SEC on August 4, 2014)
- CONSULTING AGREEMENT (Filed With SEC on August 4, 2014)
- MASTER CONSULTANCY AGREEMENT Between Nuvilex, Inc. And BB Biotech Consulting GmbH (Filed With SEC on August 4, 2014)
- MEMORANDUM OF UNDERSTANDING (Filed With SEC on August 4, 2014)
- EMPLOYMENT AGREEMENT (Filed With SEC on August 4, 2014)
- MUTUAL TERMINATION AND RELEASE AGREEMENT (Filed With SEC on May 29, 2014)
- REGISTRATION RIGHTS AGREEMENT (Filed With SEC on February 19, 2014)
- PURCHASE AGREEMENT (Filed With SEC on February 19, 2014)
- THIRD ADDENDUM TO ASSET PURCHASE AGREEMENT By and Between Nuvilex, Inc. (NVLX) And SG Austria Private Limited (SGA) Effective As Of June 25, 2013 THIRD ADDENDUM TO ASSET PURCHASE... (Filed With SEC on July 18, 2013)
- Licensing Agreement (Filed With SEC on July 18, 2013)
- REAL ESTATE SALE AGREEMENT (Filed With SEC on March 22, 2010)